Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses

Journal of Allergy and Clinical Immunology

Volumn 130, Issue 4, 2012, Pages

  Rotiroti, Giuseppina ^a   Shamji, Mohamed ^a,c   Durham, Stephen R ^a,c   Till, Stephen J ^a,b,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Grass; Ige; Immunotherapy; Intradermal; Key wordS: Tolerance; Late Response

Indexed keywords

ALLERGEN; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ARTICLE; BIRCH; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; PRIORITY JOURNAL; RANDOMIZATION; REPEATED DRUG DOSE; SKIN MANIFESTATION;

EID: 84869111317     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.06.052     Document Type: Article

References (42)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572-3.
2. Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma - a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet 1954;1:1055-7.
3. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: Therapeutic vaccines for allergic diseases - a WHO position paper. J Allergy Clin Immunol 1998;102: 558-62.
4. Rinkel HJ. The management of clinical allergy. 3. Inhalant allergy therapy. Arch Otolaryngol 1963;77:205-25.
5. Van Metre TE, Adkinson NF, Lichtenstein LM, Mardiney MR, Norman PS, Rosenberg GL, et al. A controlled-study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay-fever. J Allergy Clin Immunol 1980;65:288-97.
6. Phillips EW. Relief of hay-fever by intradermal injections of pollen extract. JAMA 1926;86:182-4.
7. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008;121:1120-5, e2.
8. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;(1):CD001936.
9. Walker SM, Durham SR, Till SJ, Roberts G, Corrigan CJ, Leech SC, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011;41:1177-200.
10. Phillips EW. Intradermal pollen therapy during the attack. J Allergy 1933;5:29-36.
11. Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacobson M, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: A randomized controlled trial. Clin Exp Allergy 2002;32:507-14.
12. Kay AB, Ying S, Varney V, Gaga M, Durham SR, Moqbel R, et al. Messenger- RNA expression of the cytokine gene-cluster, interleukin-3 (IL-3), IL-4, IL-5, and granulocyte macrophage colony-stimulating factor, in allergen-induced latephase cutaneous reactions in atopic subjects. J Exp Med 1991;173:775-8.
13. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of grass-pollen immunotherapy on cellular infiltration and cytokine messenger-RNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-51.
14. Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou TT, Ying S, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005;116:558-64.
15. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112:915-22.
16. Fling JA, Ruff ME, Parker WA, Whisman BA, Martin ME, Moss RB, et al. Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989;83:101-9.
17. Nish WA, Charlesworth EN, Davis TL, Whisman BA, Valtier S, Charlesworth MG, et al. The effect of immunotherapy on the cutaneous late-phase response to antigen. J Allergy Clin Immunol 1994;93:484-93.
18. Nasser SMS, Ying S, Meng Q, Kay AB, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001;31:3704-13.
19. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205:2887-98.
20. Krishna MT, Ewan PW, Diwakar L, Durham SR, Frew AJ, Leech SC, et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin Exp Allergy 2011;41:1201-20.
21. Muller UR, Dudler T, Schneider T, Crameri R, Fischer H, Skrbic D, et al. Type I skin reactivity to native and recombinant phospholipase A2 from honeybee venom is similar. J Allergy Clin Immunol 1995;96:395-402.
22. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011;127:89-97.
23. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94.
24. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351:2295-301.
25. Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998;32:1041-5.
26. Matriano JA, Cormier M, Johnson J, Young WA, Buttery M, Nyam K, et al. Macroflux microprojection array patch technology: A new and efficient approach for intracutaneous immunization. Pharm Res 2002;19:63-70.
27. Francis JN, Till SJ, Durham SR. Induction of IL-101CD41CD251 T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:1255-61.
28. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-9.
29. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-14.
30. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD41 CD251 cells in the nasal mucosa. J Allergy Clin Immunol 2008;121:1467-72, e1.
31. Aslam A, Chan H, Warrell DA, Misbah S, Ogg GS. Tracking antigen-specific t-cells during clinical tolerance induction in humans. PLoS One 2010;5:e11028.
32. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008;63: 1455-63.
33. Satoguina JS, Adjobimey T, Arndts K, Hoch J, Oldenburg J, Layland LE, et al. Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/ GITR-L interaction, IL-10 and TGF-beta. Eur J Immunol 2008;38:3101-13.
34. Kersey TW, Van Eyk J, Lannin DR, Chua AN, Tafra L. Comparison of intradermal and subcutaneous injections in lymphatic mapping. J Surg Res 2001;96:255-9.
35. O'Mahony S, Solanki CK, Barber RW, Mortimer PS, Purushotham AD, Peters AM. Imaging of lymphatic vessels in breast cancer-related lymphedema: Intradermal versus subcutaneous injection of 99mTc-immunoglobulin. AJR Am J Roentgenol 2006;186:1349-55.
36. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proc Natl Acad Sci U S A 2008;105:17908-12.
37. Novak N, Bieber T. Dendritic cells as regulators of immunity and tolerance. J Allergy Clin Immunol 2008;121(suppl):S370-4.
38. Romani N, Flacher V, Tripp CH, Sparber F, Ebner S, Stoitzner P. Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol 2012;351:113-38.
39. Maurer D, Fiebiger S, Ebner C, Reininger B, Fischer GF, Wichlas S, et al. Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol 1996;157:607-16.
40. Senti G, Graf N, Haug S, Ruedi N, von Moos S, Sonderegger T, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124:997-1002.
41. Reunala T, Brummerkorvenkontio H, Palosuo T. Are we really allergic to mosquito bites. Ann Med 1994;26:301-6.
42. Peng Z, Ho MK, Li C, Simons FE. Evidence for natural desensitization to mosquito salivary allergens: Mosquito saliva specific IgE and IgG levels in children. Ann Allergy Asthma Immunol 2004;93:553-6.